



February 20, 2024

## NEWS RELEASE

Company name: TMS Co., Ltd.  
Name of representative: Takuro Wakabayashi  
Chief Executive Officer  
(Securities code: 4891; Growth Market)

### **JIXING Announced the First Subject Dosing of JX09 Phase I Clinical Trial**

Tokyo, Japan February 19, 2024 TMS Co., Ltd. (the "Company") notes that its partner Ji Xing Pharmaceuticals Limited (Cayman Islands, Representative: Sandy Mou, CEO, hereinafter referred to as "JIXING"), announced today the successful dosing of the first subject in the Phase I clinical trial of JX09\* in Australia.

<https://www.jixing.com/en/media>

\* JX09 is an aldosterone synthesis inhibitor (ASI) being developed for resistant and uncontrolled hypertension, of which the Company has been granted exclusive license of development and commercialization in Japan from JIXING.

Investor and Media Contact:

[ir@tms-japan.co.jp](mailto:ir@tms-japan.co.jp)

End